Results 121 to 130 of about 71,938 (313)
Quality in SportIntroduction The goals of this paper are to present the complexity of Duchenne muscular dystrophy phenotype, genetic background, and substantial progress that has been made due to the development of genetic engineering techniques in diagnosing and ...
Anna Teresa Michalska +9 more
doaj +1 more source
Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy. [PDF]
, 2019 Many potentially therapeutic molecules have been identified for treating Duchenne muscular dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle to their clinical use.
Bertoni, Carmen +6 more
core
The FASEB Journal, Volume 39, Issue 23, 15 December 2025.We sought to determine a causal role for the microbiota in promoting dystrophic muscle characteristics by performing intra/inter‐genotype fecal microbiota transplantations (FMT) between wildtype (C57BL/10) and mdx (C57BL/10ScSn‐Dmdmdx/J) mice. We found that transplantation of mdx microbiotas into a wildtype mouse induced an mdx‐like muscle phenotype ...
James Butcher +5 more
wiley +1 more source
Case Reports in Critical Care, 2018 We describe two pediatric patients with Duchenne muscular dystrophy that presented with acute neurologic deterioration and hypoxic respiratory failure requiring mechanical ventilation.
Lee D. Murphy +2 more
doaj +1 more source
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle [PDF]
, 2023 Marcelo dos Santos Voltani Lorena +6 more
openalex +1 more source
Advanced Science, Volume 12, Issue 45, December 4, 2025.This study employed tRNASUAG, an anticodon‐engineered tRNA (ACE‐tRNA), to introduce a phosphorylatable serine into the C‐terminal domain of HBc by reading through its stop codon, thereby potentially promoting the ubiquitin‐proteasome degradation of HBc, and subsequently inhibiting HBV replication. Through a tRNASUAG‐gHBV1‐tRNASUAG‐gHBV2‐tRNASUAG tandem
Xingwen Yang +7 more
wiley +1 more source
Corticosteroid therapy in Duchenne muscular dystrophy: Management and new insights
Developmental Medicine &Child Neurology, EarlyView.
Claudia Brogna, Eugenio Mercuri
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1405-1421, December 2025.Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami +2 more
wiley +1 more source
Chinese Journal of Contemporary Neurology and Neurosurgery, 2015 The guideline "Diagnosis and management of Duchenne muscular dystrophy" was supported by a 3-year-long project guided by US Centers for Disease Control and Prevention (CDC), in collaboration with patient advocacy groups [Muscular Dystrophy Association ...
Xi-hua LI
doaj